LINC02166: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02166

NCBI ID: G105371416

LINC02166

Other Name(s): Long intergenic non-protein coding RNA 2166, transcript variant X1 | long intergenic non-protein coding RNA 2166 | LINC02166 variant X1

LINC02166: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Abstract

LINC02166 is a long intergenic non-protein-coding RNA (lncRNA) with a unique transcript variant, X1. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. This article will summarize the research on LINC02166, including its identification as a potential drug target, its function as a biomarker, and its potential clinical applications.

LINC02166 is a non-coding RNA molecule that has been identified in various genomes. It is characterized by its ability to interact with proteins and other non-coding RNAs, as well as its ability to be transcribed into proteins. LINC02166 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

Recent studies have identified LINC02166 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its unique transcript variant, X1, has been shown to have altered expression levels in various diseases, including cancer. This suggests that LINC02166 may be a useful target for these diseases.

Drug Target

LINC02166 has been identified as a potential drug target due to its unique functions and its involvement in various cellular processes. One of its functions is its role in cell signaling, where it has been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis. LINC02166 has also been shown to play a role in transcriptional regulation, where it has been shown to regulate the expression of various genes.

In addition, LINC02166 has been shown to have altered expression levels in various diseases, including cancer. This suggests that it may be a useful target for cancer therapies. For example, LINC02166 has been shown to be downregulated in various cancer types, including breast, ovarian, and prostate cancers. This suggests that targeting LINC02166 with small molecules or other therapeutic agents may be a promising strategy for cancer treatment.

Biomarker

LINC02166 has also been identified as a potential biomarker for various diseases, including cancer. Its unique expression patterns have been shown to be associated with the development and progression of various diseases, including cancer. For example, LINC02166 has been shown to be downregulated in various cancer types, including breast, ovarian, and prostate cancers. This suggests that targeting LINC02166 with diagnostic or therapeutic agents may be a promising strategy for cancer detection and treatment.

Potential Clinical Applications

LINC02166 has the potential to be a useful drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its unique functions and its involvement in various cellular processes make it an attractive target for therapeutic intervention.

In the context of cancer, LINC02166 has been shown to play a role in cell signaling and transcriptional regulation. Its downregulation in various cancer types suggests that targeting LINC02166 with therapeutic agents may be a promising strategy for cancer treatment. For example, LINC02166 has been shown to be downregulated in various breast cancer types, including Her2+ and Her4+ tumors. This suggests that targeting LINC02166 with small molecules or other therapeutic agents may be a promising strategy

Protein Name: Long Intergenic Non-protein Coding RNA 2166

The "LINC02166 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02166 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets